Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5268235
Max Phase: Preclinical
Molecular Formula: C37H63N15O9S2
Molecular Weight: 926.14
Associated Items:
ID: ALA5268235
Max Phase: Preclinical
Molecular Formula: C37H63N15O9S2
Molecular Weight: 926.14
Associated Items:
Canonical SMILES: N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
Standard InChI: InChI=1S/C37H63N15O9S2/c38-27(53)12-10-23(33(59)50-24(16-19-6-2-1-3-7-19)34(60)52-26-18-63-62-17-25(29(39)55)51-35(26)61)49-31(57)21(9-5-15-45-37(42)43)47-30(56)20(8-4-14-44-36(40)41)48-32(58)22-11-13-28(54)46-22/h19-26H,1-18H2,(H2,38,53)(H2,39,55)(H,46,54)(H,47,56)(H,48,58)(H,49,57)(H,50,59)(H,51,61)(H,52,60)(H4,40,41,44)(H4,42,43,45)/t20-,21+,22-,23-,24-,25-,26-/m0/s1
Standard InChI Key: IAJUDDNMGIAOGZ-KBRDRDRXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 926.14 | Molecular Weight (Monoisotopic): 925.4375 | AlogP: -4.18 | #Rotatable Bonds: 24 |
Polar Surface Area: 413.68 | Molecular Species: BASE | HBA: 13 | HBD: 15 |
#RO5 Violations: 3 | HBA (Lipinski): 24 | HBD (Lipinski): 19 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 10.66 | CX Basic pKa: 11.78 | CX LogP: -6.91 | CX LogD: -10.78 |
Aromatic Rings: 0 | Heavy Atoms: 63 | QED Weighted: 0.02 | Np Likeness Score: 0.23 |
1. Brust A, Croker DE, Colless B, Ragnarsson L, Andersson Å, Jain K, Garcia-Caraballo S, Castro J, Brierley SM, Alewood PF, Lewis RJ.. (2016) Conopeptide-Derived κ-Opioid Agonists (Conorphins): Potent, Selective, and Metabolic Stable Dynorphin A Mimetics with Antinociceptive Properties., 59 (6): [PMID:26859603] [10.1021/acs.jmedchem.5b00911] |
Source(1):